ArticleFrontiers in cell and developmental biology2021
Recycling Apparent Waste Into Biologicals: The Case of Umbilical Cord Blood in Italy and Spain.
Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Cord blood transfusions in extremely low gestational age neonates to reduce severe retinopathy of prematurity: results of a prespecified interim analysis of the randomized BORN trial.Italian journal of pediatrics · 2024Trial
- Cord Blood-Derived Versus Homologous Donor Platelet-Rich Plasma (PRP) in Early Knee Osteoarthritis: A Single-Center, Randomized, Double-Blind Pilot Clinical Trial.Bioengineering (Basel, Switzerland) · 2026Article
- Implementing evidence-based restrictive neonatal intensive care unit platelet transfusion guidelines.Journal of perinatology : official journal of the California Perinatal Association · 2024Review
- Achieving net-zero in the dry eye disease care pathway.Eye (London, England) · 2024Review
- Perspectives for the Use of Umbilical Cord Blood in Transplantation and Beyond: Initiatives for an Advanced and Sustainable Public Banking Program in Greece.Journal of clinical medicine · 2024Article
- Cord blood banking: Balancing hype and hope in stem cell therapy.European journal of midwifery · 2024Article
- Multi-component cord blood banking: a proof-of-concept international exercise.Blood transfusion = Trasfusione del sangue · 2023Article
- Impact of Betamethasone Pretreatment on Engrafment of Cord Blood-Derived Hematopoietic Stem Cells.Archivum immunologiae et therapiae experimentalis · 2022Article
- Impressive Nasal Septum Regeneration after Cord Blood Platelet Gel (CBPG) in Extreme Premature Neonate with Non-Invasive Ventilation: A Case Report.Children (Basel, Switzerland) · 2022Article
- Cord Blood-Derived Platelet Gel in Wound Healing: From Biological Rationale to Clinical Application.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair SocietyReview
- Characterization of growth factors in platelet-poor plasma for eye drop applications from umbilical cord blood and from allogeneic adult donor serum.Blood transfusion = Trasfusione del sangueArticle
- First use of cord blood platelet-rich plasma in the treatment of vulvar lichen sclerosus: a preliminary study towards a randomized controlled trial.Blood transfusion = Trasfusione del sangueArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most public cord blood banking programs are currently facing financial difficulties due to a progressive decline in the number of cord blood transplants performed worldwide and to a high discard rate of the donated units caused by progressively increasing thresholds of the stem cell dose required to perform safe and effective hemopoietic cord blood transplants. Recycling a proportion of unused cord blood units to prepare novel cord blood components obtained with minimal manipulation (platelets, plasma, red blood cells) and to develop more technologically complex products regulated in the US as Cellular and Gene Therapy Products and in Europe as Advanced Therapy Medicinal Products [e.g. virus-specific T cells (VST), natural killer (NK) cells, induced pluripotent stem cells (iPSCs) is a promising strategy to increase the therapeutic value and reduce the financial deficits of public cord blood banking. Based on encouraging preliminary evidences reported in the literature, additional laboratory studies, large multicenter clinical trials and international regulatory harmonization are necessary to achieve these important goals. This article describes organizational, methodological and regulatory advancements developed in Italy and Spain to promote the clinical use of cord blood platelets, plasma and red blood cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.